DVN
37
-2
PX
46
3
CSX
36
6
WYNN
25
4
DLTR
66
4
JCI
61
2
DTE
56
7
PYPL
64
6
BEN
34
4
MCO
65
3
PH
67
3
ES
45
8
EOG
50
-5
GWW
55
4
LH
52
-8
IRM
49
3
MET
60
2
DE
59
17
CVX
29
-2
EQR
44
13
DVN
37
-2
PX
46
3
CSX
36
6
WYNN
25
4
DLTR
66
4
JCI
61
2
DTE
56
7
PYPL
64
6
BEN
34
4
MCO
65
3
PH
67
3
ES
45
8
EOG
50
-5
GWW
55
4
LH
52
-8
IRM
49
3
MET
60
2
DE
59
17
CVX
29
-2
EQR
44
13
Financhill
Back

Stereotaxis 10K Form

Sell
34

STXS
Stereotaxis

Last Price:
$2.30
Seasonality Move:
-1.14%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive STXS News And Ratings

See the #1 stock for the next 7 days that we like better than STXS

STXS Financial Statistics

Sales & Book Value

Annual Sales: $26.9M
Cash Flow: $-1.8M
Price / Cash Flow: 0
Annual Sales: $0.03
Price / Book: 64.8

Profitability

EPS (TTM): -0.31000
Net Income (TTM): $-25.4M
Gross Margin: $14.6M
Return on Equity: -174.6%
Return on Assets: -57.95%

Stereotaxis Earnings Forecast

Key Stereotaxis Financial Ratios

  • The Gross Profit Margin over the past 25 years for STXS is 54.22%.
  • The Selling, General & Administrative Expenses for STXS have been equal to 109.86% of Gross Profit Margin.
  • The Research & Development expenses have been 36.26% of Revenue.
  • The Interest Expense is 17.13% of Operating Income.
  • The Net Earning history of STXS is -89.33% of Total Revenues.
  • Per Share Earnings over the last 25 years have been positive in 13 years.

Stereotaxis Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: STXS
CUSIP: 85916J
Website: stereotaxis.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.07
Quick Ratio: 0.62

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

STXS Technical Analysis vs Fundamental Analysis

Sell
34
Stereotaxis (STXS) is a Sell

Is Stereotaxis a Buy or a Sell?

  • Stereotaxis stock is rated a Sell
    The current Stereotaxis [STXS] share price is $2.17. The Score for STXS is 34, which is 32% below its historic median score of 50, and infers higher risk than normal.